Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.
Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu D, Qu Y, Zheng G, Li L, Ji Y, Yin G, Huang W, Xie Y, Yang X, Gao X, An P, Xue F, Li H, Deng H, Li L, Pei L, Qian L.
Huo Y, et al. Among authors: gao x.
Lancet Reg Health West Pac. 2023 Sep 28;41:100907. doi: 10.1016/j.lanwpc.2023.100907. eCollection 2023 Dec.
Lancet Reg Health West Pac. 2023.
PMID: 37808342
Free PMC article.